Objective. National guidelines highlight the roles of early HIV diagnosis and effective comanagement for HIV and tuberculosis (TB) to prevent mortality and morbidity from HIV-related TB . We assessed HIV diagnosis timing and HIV/TB comanagement for California HIV/TB patients .
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Objective. National guidelines highlight the roles of early HIV diagnosis and effective comanagement for HIV and tuberculosis (TB) to prevent mortality and morbidity from HIV-related TB . We assessed HIV diagnosis timing and HIV/TB comanagement for California HIV/TB patients .
Methods. We reviewed and analyzed public health charts for California HIV/TB patients reported during 2008 . HIV diagnoses fewer than three months before TB diagnosis were considered new HIV diagnoses . We determined the proportion of patients with new HIV diagnoses, risk factors for new HIV diagnoses, and proportion of patients receiving recommended CD4 cell count measurements, supervised TB therapy, and antiretroviral therapy (ART) .
results. Of 130 HIV/TB patients, 51% had new HIV diagnoses . Foreign-born patients were more likely than U.S.-born patients to have new HIV diagnoses. Supervised TB therapy and CD4 cell count measurements followed national recommendations for 91% and 74% of patients, respectively . At least 73% of patients started ART before completing TB therapy . Compared with patients who had previous HIV diagnoses, patients with new HIV diagnoses started ART later and had lower CD4 cell counts and higher viral loads at TB diagnosis .
Conclusions. Although most HIV/TB patients received the recommended treatment, half had new HIV diagnoses . Compared with patients who had previous HIV diagnoses, patients with new HIV diagnoses had greater immunosuppression at TB diagnosis . A new diagnosis indicates that HIV could have been diagnosed earlier and ART or treatment for latent TB infection could have been initiated to prevent TB development .
Human immunodeficiency virus (HIV) infection is a potent risk factor for death among tuberculosis (TB) patients. [1] [2] [3] [4] [5] In the United States during 2006, HIVinfected patients comprised 12% of TB patients with known HIV status but 30% of patients who died during TB therapy. 1 Among all states, California reported the largest number of TB patients and the second-largest number of patients diagnosed with HIV infection in 2009. 6, 7 A field assessment in California found that 132 TB patients had HIV in 2008, 8 accounting for 14% of all TB patients with HIV in the U.S. 9 Timely HIV diagnosis is an important step in preventing TB disease and HIV/TB mortality. Early HIV diagnosis informs patients of their risk for developing TB disease and triggers opportunities to prevent TB through isoniazid prophylaxis and antiretroviral therapy (ART). 10 Isoniazid prophylaxis effectively reduces the risk of progression to TB disease among HIVinfected patients with latent TB infection (LTBI). 11 ART restores immune function and is estimated to reduce the risk of TB in HIV-infected patients by 65%. 12 ART even reduces the TB risk in people without a positive tuberculin skin test, suggesting a possible protective effect against establishment of infection by Mycobacterium tuberculosis. 13, 14 Even when LTBI progresses to TB disease in patients unaware of their HIV infection, HIV diagnosis is still critical because providers are alerted to patients' need for ART, which can reduce the risk of death. 4 Providers can also make referrals to HIV services and coordinate HIV/TB comanagement. Therefore, HIV status determination is recommended for all TB patients. 2 Once TB patients with HIV infection are identified, effective HIV/TB comanagement is needed to optimize patient outcomes. Recommendations from the Office of AIDS Research Advisory Council (OARAC) help TB clinicians ensure effective comanagement. 15 TB clinicians should obtain cluster of differentiation 4 (CD4) cell counts to monitor HIV progression and determine the timing of ART. Clinicians should also ensure supervision of TB therapy to enhance adherence and prevent acquired TB drug resistance. At the time of the 2008 OARAC recommendations, there was insufficient evidence to determine the optimal timing of ART initiation during TB therapy. Although the 2008 guidelines did not make formal recommendations, they suggested that ART be started two weeks after TB treatment initiation for patients with ,100 CD4 cells/millimeter cubed (mm 3 ), eight weeks after TB treatment initiation for patients with 100-200 CD4 cells/mm 3 , and based on clinical judgment for patients with 200 CD4 cells/mm 3 
MetHoDS

Study population
We conducted a retrospective review of public health records for all TB patients reported in 2008 from California to identify HIV/TB patients. Public health records included patient charts and databases maintained by local TB programs to monitor and manage TB cases. HIV/TB patients had any of the following before TB therapy completion: (1) positive HIV test results, (2) self-report of positive HIV status, (3) provider report of a positive HIV status, or (4) report of patient receiving ART medication. Public health records of HIV/TB patients underwent a second review to assess the timing of HIV testing and HIV/TB comanagement parameters. We collected information on HIV diagnosis timing, supervision of TB therapy, ART initiation, CD4 cell counts, viral loads, and mortality. These data were then merged with individual demographic and clinical data from the state TB registry.
Definitions
Patients were classified according to the relative timing of their HIV and TB diagnoses. The TB diagnosis date was defined as the earliest of the TB case report date, collection date of the first positive sputum culture, or TB therapy start date. Patients with an HIV diagnosis more than three months before TB diagnosis were classified as having a previous HIV diagnosis; all others were classified as having a new HIV diagnosis. This classification scheme allowed us to identify patients diagnosed with HIV infection during TB diagnosis, assuming the TB diagnostic period could take up to three months. We also classified patient providers according to their association with local health department TB programs. TB provider type was associated with TB programs if patient care was delivered by local health department TB programs or by clinics associated with local TB programs. All other providers, including some county hospital clinicians not related to local TB programs, were unassociated with TB programs. Overall TB management was dichotomized as either associated with TB programs (having any management by providers associated with TB programs) or completely unassociated with TB programs. Calendar weeks when patients were hospitalized for at least one day were considered hospitalization weeks. If the first and second calendar weeks of TB therapy were hospitalization weeks, the patient was considered hospitalized during TB diagnosis.
We also examined CD4 cell count and viral load measurements at TB diagnosis. The measurement at TB diagnosis was defined as the test result closest to the TB diagnosis date and within 90 days of it. When measurements were before and after TB diagnosis and were also an equal amount of time from the TB diagnosis date, the earliest test result was used as the measurement at TB diagnosis. Measurements within 90 days of TB diagnosis but on an unknown day of the month were considered to have occurred on the 15th day of the specified month.
We assessed initial supervision of TB therapy and ART initiation during TB therapy. Patients who initiated directly observed therapy (DOT) within the first 56 days of TB therapy and patients who were hospitalized, jailed, or in rehabilitation facilities for the first 56 days of TB therapy were considered to have initially supervised TB therapy. Patients who received at least one antiretroviral dose during TB therapy were considered to have received ART during TB therapy.
When analyzing patient characteristics associated with a new HIV diagnosis, we identified patients with a previous TB episode. Patients with another TB diagnosis more than 12 months before their current one were considered to have a previous TB episode.
Statistical analysis
We calculated the proportion of HIV/TB patients with a new HIV diagnosis and examined specific demographic and clinical characteristics of this group, including age; sex; race/ethnicity; foreign birth; site of TB disease; previous TB episode; history of incarceration, homelessness, excess alcohol use, or illicit drug use; and provider of TB management. We used bivariate logistic regression to identify factors associated with a new HIV diagnosis and to calculate odds ratios (ORs) and 95% confidence intervals (CIs). We used Fisher's exact test to calculate p-values when sample sizes were small. Factors with p,0.20 were included in a multivariate model. We then used backwards-stepwise hierarchical selection to identify independently significant factors using multivariate logistic regression and calculate adjusted ORs (AORs).
To measure adherence to the 2008 OARAC guidelines, we determined the proportion of patients with initially supervised TB therapy and CD4 cell counts at TB diagnosis. We also determined the proportion of patients who started ART before TB therapy completion and when ART was started.
We (Table 2 ). There were no significant differences in these practices between patients with a new HIV diagnosis and patients with a previous HIV diagnosis. Of 63 patients who had a previous HIV diagnosis, 38 (60%) started ART before TB therapy initiation. Of the 64 patients who had a new HIV diagnosis, only seven (11%) started ART before TB therapy initiation (p,0.001) ( Table 2 ). Of the 23 patients who did not receive ART during TB therapy, 15 had at least one documented reason why it was not given. Reasons for not receiving ART included death (n54), loss to follow-up (n54), nonadherence to TB therapy (n53), homelessness (n52), substance abuse (n52), and concerns about immune reconstitution inflammatory syndrome (n52) (data not shown).
Providers unassociated with TB programs played a major role in initial TB care for HIV/TB patients. Among the 127 patients starting TB treatment, providers unassociated with TB programs diagnosed TB in 121 (95%) patients and initiated TB treatment in 101 (80%) patients. However, there was no difference in initiating ART between providers associated with TB programs and providers unassociated with TB programs (data not shown).
Immune function, hospitalization, and death
Among patients who started TB therapy, those with a previous HIV diagnosis had less advanced immunosuppression at TB diagnosis than those who had a new HIV diagnosis, as measured by CD4 cell count and viral load ( Table 3 ). Hospitalization at TB diagnosis was more likely among patients with a new HIV diagnosis than among patients with a previous HIV diagnosis, but this difference was not statistically significant.
There was no difference between patients with a new HIV diagnosis and patients with a previous HIV diagnosis in the proportion of patients dying before TB treatment completion. We also examined deaths by CD4 cell count. Death occurred for seven (16%) of 44 patients with ,100 CD4 cells/mm 3 and for three (5%) of 59 patients with 100 CD4 cells/mm 3 (p50.073). Five additional patients died, but they did not have CD4 cell count information (data not shown). Compares the proportion of patients starting ART before TB treatment initiation among those who started ART b Includes patients whose ART start was inexact but before TB treatment week 9 c Includes patients whose ART start was inexact but during TB treatment HIV 5 human immunodeficiency virus TB 5 tuberculosis CD4 5 cluster of differentiation 4
ART 5 antiretroviral therapy
DiScuSSion
Our findings suggest a need for earlier HIV diagnosis and treatment initiation to prevent TB. It is concerning that nearly half of California HIV/TB patients in 2008 had new HIV diagnoses. Such patients were unaware of their HIV infection and, thus, might have missed opportunities to prevent TB through ART and isoniazid prophylaxis. Delayed HIV diagnosis has been recognized as a major problem in the U.S. An estimated 20% of HIV-infected people were undiagnosed in 2008, 17 and 33% of people diagnosed with HIV in 2008 developed acquired immunodeficiency syndrome (AIDS) within a year. 6 In California, 61% of AIDS patients diagnosed from 2000 to 2006 had their first HIV diagnosis within a year of AIDS diagnosis. 18 In California, like the rest of the country, there is a need to address this gap by improving HIV testing outreach and education efforts in addition to HIV prevention activities.
Because foreign-born people are at increased risk for TB in the U.S., 19 it is especially important to target HIV testing efforts toward this population. Although the U.S. Centers for Disease Control and Prevention recommended testing all people aged 13-64 years in health-care settings for HIV in 2006, 20 this population is still unreached. In our evaluation of HIV/TB patients, foreign-born people (100% of Asian and 85% of Hispanic people) were more likely to have a new HIV diagnosis. This finding is consistent with national findings that foreign birth is a strong predictor of late HIV testing in the U.S. [21] [22] [23] [24] Research has shown that undocumented status, lack of health insurance, perceived lack of risk, and stigma contribute to delayed HIV testing among foreign-born people. 22, 25, 26 Foreign-born people often have limited access to care. 27 Low-cost HIV testing outside of traditional health-care settings, education on HIV risks, and promotion of early testing and care may increase early HIV diagnosis among foreign-born patients. Because previous research on HIV testing among foreign-born patients has focused largely on Hispanic populations, additional studies are needed to identify barriers and potential interventions for foreign-born Asian people.
Early HIV diagnosis and care in patients at risk for TB present opportunities to prevent TB. ART, LTBI testing, and isoniazid prophylaxis are highly effective TB prevention measures and are key strategies to mitigate epidemics of HIV-associated TB. 28, 29 ART soon after HIV infection is essential because the risk of TB decreases as CD4 cell counts increase. 30 Effective strategies exist to prevent HIV-associated TB, but gaps in HIV detection may hinder their effective implementation. Although early HIV diagnosis was associated with improved immune function at TB diagnosis, our evaluation may have been underpowered to identify an association with improved outcomes. Patients with previous HIV diagnoses had higher CD4 cell counts at TB diagnosis than patients who had new HIV diagnoses. Other studies have shown that higher CD4 cell counts have been associated with improved TB survival, 31-33 but we did not observe improved survival among patients with previous HIV diagnoses. However, our evaluation included only 15 deaths. We also found that patients with previous HIV diagnoses were less likely to be hospitalized at TB diagnosis, but this difference was not statistically significant.
Once HIV infection was identified, most TB patients received recommended HIV/TB comanagement based on measures we examined. Of the patients starting TB therapy, 74% had CD4 cell count measurements and 91% had initially supervised TB therapy. However, there is room for improvement, as only 73% of HIV/TB patients initiated ART before TB therapy completion. Some patients did not receive ART due to substance abuse, homelessness, and nonadherence to treatment. Yet, social support can address ART adherence concerns in drug-abusing and homeless populations. 34, 35 And although the 2008 OARAC guidelines noted insufficient evidence regarding the timing of ART during TB treatment, recent studies demonstrate that ART during TB therapy reduces TB mortality among the most immunocompromised individuals in developing country settings. [36] [37] [38] [39] As a result, OARAC released updated guidelines in 2012 formally recommending ART initiation within two weeks of TB treatment initiation for patients with ,50 CD4 cells/mm 3 , 2-4 weeks after TB treatment initiation for those with severe clinical disease, and 8-12 weeks after TB treatment initiation for those without severe clinical disease. 40 These new guidelines should prompt providers to attempt the provision of lifesaving ART treatment for all HIV/TB patients.
Public health TB programs can initiate and direct improvements in HIV/TB comanagement among providers outside of TB programs, who play a major role in TB diagnosis and initial TB care. TB programs are responsible for linking HIV/TB patients to HIV care and coordinating TB therapy accordingly. To facilitate optimal care, TB programs should (1) ensure measurement and documentation of CD4 cell counts for all HIV/TB patients and (2) ensure administration and documentation of DOT and ART. Gaps in monitoring CD4 cell counts, supervising TB therapy, or initiating ART should stimulate interventions such as provider education.
Limitations
This study was subject to several limitations. First, if patients lacked documentation of recommended care, we could not distinguish whether it was because care was truly inadequate or because receipt of adequate care was incompletely documented. Incomplete documentation in the public health record would have caused misclassification, especially among patients managed outside of TB programs. Secondly, the small sample size limited our multivariate and outcome analysis. Lastly, our evaluation included patients from 2008 only. Therefore, estimates may not reflect the most recent practices. However, they were the most recent data available at the time of study initiation, and these data provide an important baseline for practices among HIV/TB cases in California.
concluSionS Based on our evaluation, there is likely a need for earlier HIV diagnosis and care, particularly among foreignborn people at risk for TB in California. Almost half of California's HIV/TB patients had new HIV diagnoses and missed opportunities for TB prevention. These patients started ART later and had more advanced immunosuppression than patients who had previous HIV diagnoses. Outreach and education should target foreign-born people at risk for TB to identify HIV infection earlier and link them to HIV care and TB preventative care. Public health TB programs should continue to monitor HIV/TB comanagement data to ensure adherence to guidelines. 
